Red ones are the drugs that are discontinued during trials and not discussed
Table 2
Among the drugs mentioned in the table only aprepitant and fosaprepitant could be marketed. Many others have been discontinued in the developmental stage itself. Some trials are ongoing like Aprepitant for Advanced small cell carcinoma(NCT04840004). Aprepitant was also tried for Alcohol craving and PTSD(NCT00896038) which was completed but trial results were not available. Interestingly aprepitant was also tried for HIV infection which failed to show viral load reduction.71 DNK-333 which was tried for IBS in two trials [(NCT00699166) and (NCT00394173)] produced significant subjective relief of symptoms in IBS but not with stool consistency which was the primary endpoint of the trial. Vestipitant was another agent tried for Tinnitus but showed no clinically significant results.72Vofopitant was another drug tried for PTSD but showed efficacy not better than placebo.73Ibodutant another drug which was evaluated for IBS showed better efficacy when compared to placebo in symptomatic improvement when compared to placebo.74TA-5538 was tried for overactive bladder in a trial in Japan and was discontinued for undisclosed reasons. SSR 240600 was tried in a trial called BILADY for which results were not published (NCT00564226). LY-686017 which was tried for social anxiety disorder showed no significant difference in Leibowitz social anxiety scale (LSAS) when compared to placebo (NCT00191002).75 Orvepitant was tried for MDD but the trial was terminated since seizures occurred in patients during the trial period (NCT00880399). Rolapitant was studied for its effects in PONV but the results of the trial were not published (NCT00539721). Casopitant was another drug which was tried for a number of conditions, its efficacy for overactive bladder was evaluated but terminated due to undisclosed reasons (NCT00332319). The same drug was tried for fibromyalgia and this trial was completed but results were not published (NCT00264628). Similar is the case with primary insomnia [(NCT00280423), (NCT00280436), (NCT00354809)]. For CINV the manufacturers approached European medicines agency for marketing authorisation application but withdrawn in September 2009 by the manufacturers76 So again as like bradykinins the modalities to target tachykinins were also not so straightforward other than cases of PONV and CINV Even though research continues in this field and successful drug development for other indications might become feasible.